Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Don bayani kawai — ba shawarar likita ba ne
Yaya tsananinsa?
Haɗarin mutuwa
Eh
Allurar rigakafi tana nan?
Lokacin zuwa alamomi
Ƙasashen da abin ya shafa
Annobar da ke gudana
An hada ta cikin allurar MMR — ka tabbatar da allura 2 kafin tafiya. Hadarin ya yi kadan ga matafiya da suka kammala allurar rigakafi. Barkewar cuta tana faruwa a wuraren da mutane ke hulda da juna (gidajen dalibai, jiragen ruwa). Idan ka samu kumburin glandin miyau tare da zazzabi, ka nemi binciken likita.
Maruru (mumps) cuta ce mai yaduwa da kwayar cutar paramyxovirus ke haifarwa. Tana kumbura glandar salivary kusa da kunne.
Viral infection primarily affecting the salivary glands.
Mumps cuta ce ta kwayar cuta (virus) da mumps rubulavirus ke haddasa ta. Tana sa kumburin glandin miyau (parotid glands) wanda ke haifar da ciwo. Kashi 30–40% na kamuwa ba sa nuna alamun cuta. Matsalar da ta fi hatsari ita ce kumburin gwaiwa (orchitis) a maza da suka wuce shekarun balaga (15–30%). Allurar MMR tana samuwa a cikin shirin rigakafin Najeriya. Cuta ce da dole a bayar da rahotonta.
Ciwo mai tsanani a gwaiwa (a fitar da juyin gwaiwa — gaggawa ta likitan tiyata). Alamun kumburin membrane din kwakwalwa. Farfadiya.
Alamomi da alamu mafi yawa
Lokacin kwanciyar cuta: Kwanaki 12–25. Kumburin glandin miyau mai ciwo (daya bangare → biyu a 70–80%). Wahalar tauna da hadiya. Kumburin gwaiwa (orchitis) a maza da suka wuce balaga (15–30%): ciwo mai tsanani da kumburi. Kumburin membrane din kwakwalwa (aseptic meningitis, 1–10%). Kumburin pancreas (2–5%). Kurame (1/20,000).
Sanin alamomi shine mataki na farko don amsa cikin sauri.
Matakan cutar haɓƙo:
Kamuwa ba tare da alamomi ba: 20–30% na kamuwar haɓƙo ba su da alamomi. Wasu 40–50% suna nuna alamomin numfashi marasa takamaiman kawai.
Yadda ake gano wannan cutar
RT-PCR (swab daga bakin glandin Stensen). IgM antibodies na mumps. IgG na lokuta biyu. Bayar da rahoto ga hukumomi dole ne.
Hanyoyin magani da ake da su
Tallafin jiki: keɓe kwanaki 5, magungunan rage ciwo/zazzabi, ɗamara a kan glandin miyau, abinci mai laushi. Kumburin gwaiwa: hutawa a gado, tallafin scrotal, magungunan rage kumburi (NSAIDs).
Yawancin lokuta ana magance su yadda ya kamata tare da gano cutar da wuri.
Yadda za ka kare kanka
Allurar MMR: allurai biyu. Ingancin kariya: 78% (allura daya), 88% (allurai biyu). Allura ta uku a lokacin barkewar cuta.
Shirye-shirye shine mafi kyawun kariya.
Ka tabbatar an yi maka allurai biyu na MMR kafin tafiya. Hadari a wuraren kwana na tare (shirye-shiryen musayar dalibai, hostels).
Ƙididdiga da bayanan yanki
Ana samun barkewar cutar a tsakanin matasa masu zaune tare (jami'o'i, sansanin soji). Najeriya: shari'o'i da ba a sanar da su ba saboda karancin sa ido. Cutar ba ta da tsananin hatsari idan ba a barkewar annoba ba.
Wanene ke cikin haɗarin mafi girma
Risk factors for mumps infection:
Vaccination status: Unvaccinated or incompletely vaccinated individuals have the highest risk. However, waning immunity means that even two-dose MMR recipients become increasingly susceptible over time (particularly >10 years after the second dose).
Close-contact settings: University dormitories, military barracks, boarding schools, prisons, and sports teams create ideal conditions for transmission. Most contemporary outbreaks in vaccinated populations occur in these settings.
Age: In the prevaccine era, peak incidence was in children aged 5–9 years. In the vaccine era, outbreaks have shifted to young adults (18–25 years), reflecting waning immunity from childhood vaccination.
Travel: Exposure to regions with endemic mumps or ongoing outbreaks, particularly areas with low MMR coverage.
Crowding and shared living spaces: Household secondary attack rate in susceptible contacts is 40–50%.
Risk factors for complications:
Post-pubertal age: Orchitis occurs almost exclusively in post-pubertal males (15–30% of post-pubertal male mumps cases vs. <1% in prepubertal boys). Oophoritis occurs in 5% of post-pubertal females.
Age >15 years: Meningitis and encephalitis are more common in adolescents and adults than in young children.
Male sex: Males are 3–5 times more likely to develop mumps encephalitis than females.
Immunosuppression: Limited data, but immunocompromised individuals may have atypical presentations and prolonged viral shedding.
Genotype: Some evidence suggests that genotype G (currently dominant globally) may be associated with higher rates of complications in vaccinated populations, possibly due to antigenic differences from the Jeryl Lynn vaccine strain (genotype A), though this remains debated.
Rikitarwa da za ta iya faruwa
Kumburin gwaiwa (orchitis, 15–30%): raguwar gwaiwa a 50%, rashin haihuwa ba safai ba. Kumburin kwai (oophoritis, 5%). Kumburin membrane din kwakwalwa (1–10%): yawanci ba shi da hatsari. Kumburin kwakwalwa (encephalitis, 1/6,000). Kurame na jijiyoyin ji (1/20,000). Mutuwa: 1.6–3.8/10,000.
Sakamakon da ake tsammani da murmurewa
Gabaɗaya: Kyakkyawan hasashen warkarwa. CFR ~0.01%. Cutar tana warke da kanta a mafi yawan marasa lafiya.
Matsaloli:
Kumburin gwaiwa (orchitis): 15–30% na maza bayan balaga. Na ɓangarorin biyu a cikin 15–30% na marasa lafiyar orchitis. Raguwar haihuwa ba kasafai ba (ƙasa da 5%); rashin haihuwa gaba ɗaya ba ya yiwuwa.
Kumburin kwai na mace (oophoritis): 5% na mata bayan balaga.
Kumburin fatar ƙwaƙwalwa mara ƙwayoyin cuta: 1–10% (yawanci mara haɗari, yana warke cikin kwanaki 3–10).
Rashin ji na jijiyoyi: 1 a cikin 20,000 (yawanci na gefe ɗaya, na iya zama na dindindin).
Kumburin pancreas: 4% (yawanci mai sauƙi, yana warke da kansa).
Rigakafi: Na dindindin bayan kamuwa ta halitta. Rigakafin allurar na iya raguwa (gazawar allurar ta biyu na taimakawa wajen barkewar cutar a cikin al'ummomin da aka yi musu allurar rigakafi).
Ana iya hana wannan cuta ta hanyar allurar rigakafi. Kariya mai inganci tana samuwa.
Yi magana da ƙwararren lafiyar tafiya game da jadawalin da aka ba da shawarar kafin tafiyar ku.
Nemo asibitin allurar rigakafi →Abun ciki a wannan shafin don bayani da ilimi ne kawai. Ba ya zama shawarar likita, gano cuta, ko shawarwarin magani ba. Idan kuna da damuwar lafiya, tuntuɓi ƙwararren ma’aikacin lafiya. SafeTripVax ba mai ba da sabis na likitanci ba ne.
Cikakkun sharuɗɗan amfaniRecent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
And 15 more records
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →Kun san allurar rigakafin da kuke bukata? Da kyau. Ba ku sani ba? Ku gaya mana inda kuke tafiya — za mu nemo allurar da ta dace da asibiti. Kyauta, ba tare da wani hakki ba.